HCPLive Network

Drug Reduces Progression to Clinically Definite MS

Friday, April 20 (HealthDay News) --  As part of a Phase 3 trial, Mark Freedman, M.D., from the University of Ottawa in Canada, and colleagues randomly assigned 517 individuals who had a first clinical demyelinating event and brain lesions detected by magnetic resonance imaging (MRI) to a subcutaneous serum-free formulation of IFN β-1a one or three times a week, or placebo. Placebo patients were switched to IFN β-1a three times a week after two years or after a diagnosis of clinically definite MS.

At three years, the researchers found that the probability of developing clinically definite MS was 41.3 percent for placebo patients switched to IFN β-1a, but was significantly lower for those who received IFN β-1a once a week (27.6 percent) or three times a week (27.1 percent). Similar results were found for the probability of a McDonald MS diagnosis, at 86.5, 79.1, and 66.8 percent, respectively.

"While doses three times a week and once a week equally delayed a clinically definite MS diagnosis without MRI measures, there were significantly more benefits in taking the drug three times a week compared with once a week when it came to brain lesion changes and other McDonald criteria for diagnosing MS," Freedman said in a statement.

The study was supported by Merck Serono S.A.

Press Release
More Information

Individuals suspected of having multiple sclerosis are less likely to be diagnosed with clinically definite disease if they soon start treatment with interferon β-1a, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 28 in New Orleans.




Copyright © 2012 HealthDay. All rights reserved.


Further Reading
A Manhattan Research survey recently found that many physicians believe digital communication technologies, including mobile apps, can be used to improve patient outcomes, according to an article published Oct. 8 in Medical Economics.
A strong brand is the Holy Grail for marketers, and should be for physicians. A brand is a promise that the product or service will be consistent and reliable every time. And it differentiates the product or service from competitors. It is a means to more sales and to a premium price so everyone in search of revenue places a strong brand identity as Job 1.
Duration of palsy should be considered when selecting candidates for surgical management of painless foot drop in patients with degenerative lumbar disorders, according to research published in the October issue of the Journal of Spinal Disorders & Techniques.
The cost to implement ICD-10 were already estimated to be dramatically more expensive than initially thought. Now, with another one-year delay, practices will face more expenses.
While industry analysts expected Medicaid expansion states would see larger increases in paying customers compared to non-expansion states, the gap was far greater than predicted.
Malpractice reform may not keep physicians from ordering unnecessary and expensive tests, according to a study published in the Oct. 16 issue of the New England Journal of Medicine.
With prevalence rates for autism spectrum disorder higher than previously estimated, clinicians should be aware of recent changes in diagnostic definitions and criteria for autism spectrum disorder.
More Reading